Massimo Di Nicola

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 7

Top Venues

Journal for immunotherapy of cancer

Cancers

Cellular oncology (Dordrecht)

Hematological oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Schenker, Mauricio Burotto, Martin Richardet, Tudor-Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schoffski, Paolo Antonio Ascierto, Michele Maio, Iwona Lugowska, Lorena Lupinacci, Alexandra Leary, Jean-Pierre Delord, Julieta Grasselli, David S P Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Journal for immunotherapy of cancer 12 (8) (2024)
Michael Schenker, Mauricio Burotto, Martin Richardet, Tudor-Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schoffski, Paolo Antonio Ascierto, Michele Maio, Iwona Lugowska, Lorena Lupinacci, Alexandra Leary, Jean-Pierre Delord, Julieta Grasselli, David S P Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Journal for immunotherapy of cancer 12 (8) (2024)
Michael Schenker, Mauricio Burotto, Martin Richardet, Tudor-Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schoffski, Paolo Antonio Ascierto, Michele Maio, Iwona Lugowska, Lorena Lupinacci, Alexandra Leary, Jean-Pierre Delord, Julieta Grasselli, David S P Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Journal for immunotherapy of cancer 12 (8) (2024)
Francesca De Santis, Sandra L Romero-Cordoba, Lorenzo Castagnoli, Tatiana Volpari, Simona Faraci, Giovanni Fucà, Elda Tagliabue, Filippo De Braud, Serenella M Pupa, Massimo Di Nicola
BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer. Cellular oncology (Dordrecht) 45 (2) (2022)
Francesco Mainini, Francesca De Santis, Giovanni Fucà, Massimo Di Nicola, Licia Rivoltini, Michael R Eccles
Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer. Cancers 13 (15) (2021)
Alessandro Satta, Mezzanzanica Delia, Francesco Caroli, Barbara Frigerio, Massimo Di Nicola, Roland E Kontermann, Federico Iacovelli, Alessandro Desideri, Silvana Canevari, Alessandro Massimo Gianni
Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. mAbs 10 (7) (2018)
Anna Rossini, Franco Zunino, Giusi Ruggiero, Michelandrea De Cesare, Denis Cominetti, Monica Tortoreto, Cinzia Lanzi, Giuliana Cassinelli, Roberta Zappasodi, Claudio Tripodo, Alessandro Gulino, Nadia Zaffaroni, Massimo Di Nicola
Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat. Hematological oncology 36 (1) (2017)

Massimo Di Nicola.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Massimo Di Nicola